Jasti Choudary, PhD

Articles by Jasti Choudary, PhD

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

ByGeorge Shashaty, MD,Raymond Frankewich, PhD,Tamal Chakraborti, PhD,Jasti Choudary, PhD,Suliman Al-fayoumi, PhD,Alice Kacuba, RN, MSN,Sonia Castillo, PhD,Kathy Robie-suh, MD, PhD,Dwaine Rieves, MD,Karen Weiss, MD,Richard Pazdur, MD

December 1st 2006

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.

Latest Updated Articles

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis
Published: December 1st 2006 | Updated:

Jasti Choudary, PhD

Articles by Jasti Choudary, PhD

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

Latest Updated Articles

Trending on CancerNetwork

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

Anti-TIGIT Combination Therapy Yields Positive Survival in Gastric Cancers

Fruquintinib Combo Prolongs PFS in Advanced/Metastatic RCC

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma